Axinn Advised Thermo Fisher on $1.85B Acquisition of PeproTech, Inc.
January 5, 2022
Axinn represented Thermo Fisher Scientific Inc., the world leader in serving science, in its approximately $1.85 billion acquisition of PeproTech, Inc., a leading developer and manufacturer of recombinant proteins. The deal closed on December 30, 2021. The Axinn antitrust team included partners John Harkrider and Mark Alexander, who were assisted by Craig Minerva, Tasneem Chowdhury, Megan Walden, and Kyle Sherwood.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
30th Annual IBA Competition Conference
Speaking Engagement
Antitrust
Women Leaders in Life Sciences Law
Speaking Engagement
Litigation & Trials
What's the Skinny on SCOTUS' Skinny Label Decision?
Webinar
Intellectual Property
National Bar Association Corporate Counsel Leadership Summit
Speaking Engagement
Antitrust
DC Bar: The DOJ's New Antitrust Whistleblower Rewards Program: An Overview and the Road Ahead
Speaking Engagement
Antitrust
The ITC's Strategic Reset: One year after Lashify and the revival of Fintiv
Byline Articles
Intellectual Property
Axinn Partner John DeQ. Briggs Endows Antitrust Professorship at Georgetown Law
News
Antitrust
Informa Antitrust Midwest 2026
Speaking Engagement
Antitrust
Too Much or Not Enough? Healthcare Organizations Comment on the New HSR Form
Axinn Viewpoints
Antitrust
Axinn Partner Scott Eisman Selected as Rising Star in New York Law Journal’s 2026 New York Legal Awards
Awards & Recognitions
Litigation & Trials